NO20055986L - Forbindelse for behandling og forebygging av virale infeksjonssykdommer - Google Patents

Forbindelse for behandling og forebygging av virale infeksjonssykdommer

Info

Publication number
NO20055986L
NO20055986L NO20055986A NO20055986A NO20055986L NO 20055986 L NO20055986 L NO 20055986L NO 20055986 A NO20055986 A NO 20055986A NO 20055986 A NO20055986 A NO 20055986A NO 20055986 L NO20055986 L NO 20055986L
Authority
NO
Norway
Prior art keywords
compound
infectious diseases
viral infectious
prevention
same
Prior art date
Application number
NO20055986A
Other languages
English (en)
Inventor
Takuo Tsukuda
Takeshi Murata
Masayuki Sudoh
Miyako Masubuchi
Kenichi Kawasaki
Fumio Watanabe
Hiroshi Fukuda
Susumu Komiyama
Tadakatsu Hayase
Original Assignee
Chugai Pharmaceutical Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Chugai Pharmaceutical Co Ltd filed Critical Chugai Pharmaceutical Co Ltd
Publication of NO20055986L publication Critical patent/NO20055986L/no

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C231/00—Preparation of carboxylic acid amides
    • C07C231/02—Preparation of carboxylic acid amides from carboxylic acids or from esters, anhydrides, or halides thereof by reaction with ammonia or amines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
    • A61K31/215—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids
    • A61K31/216—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acids having aromatic rings, e.g. benactizyne, clofibrate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/403—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
    • A61K31/404—Indoles, e.g. pindolol
    • A61K31/405—Indole-alkanecarboxylic acids; Derivatives thereof, e.g. tryptophan, indomethacin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C235/00—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by oxygen atoms
    • C07C235/70—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by oxygen atoms having carbon atoms of carboxamide groups and doubly-bound oxygen atoms bound to the same carbon skeleton
    • C07C235/72—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by oxygen atoms having carbon atoms of carboxamide groups and doubly-bound oxygen atoms bound to the same carbon skeleton with the carbon atoms of the carboxamide groups bound to acyclic carbon atoms
    • C07C235/76—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by oxygen atoms having carbon atoms of carboxamide groups and doubly-bound oxygen atoms bound to the same carbon skeleton with the carbon atoms of the carboxamide groups bound to acyclic carbon atoms of an unsaturated carbon skeleton

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Virology (AREA)
  • Emergency Medicine (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Immunology (AREA)
  • Molecular Biology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • AIDS & HIV (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Peptides Or Proteins (AREA)
  • Pyridine Compounds (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
  • Indole Compounds (AREA)
  • Heterocyclic Compounds Containing Sulfur Atoms (AREA)
  • Epoxy Compounds (AREA)
  • Hydrogenated Pyridines (AREA)

Abstract

Forbindelse egnet til å hindre og behandle virale infeksjonssykdommer, og særlig leversykdommer forårsaket av HCV-infeksjon. Forbindelsen har en høy grad av replikerings-inhiberende aktivitet mot HCV, representert ved formelen (I): (der A representerer -(CH2)n-, osv; B representerer -(C=O)-, osv; D representerer -(CH2)m-R', osv; E representerer et hydrogenatom, osv; G representerer -(CH2)p-J, osv; binding Q representerer ei enkeltbinding eller dobbeltbinding; og R1, R2 og R3 kan være lik eller ulik og representerer hver et hydrogenatom, osv), et prodrug av samme eller et farmasøytisk akseptabelt salt av samme.
NO20055986A 2003-07-09 2005-12-16 Forbindelse for behandling og forebygging av virale infeksjonssykdommer NO20055986L (no)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
JP2003272420 2003-07-09
PCT/JP2004/009803 WO2005005372A1 (ja) 2003-07-09 2004-07-09 抗ｈｃｖ作用を有する化合物およびその製法

Publications (1)

Publication Number Publication Date
NO20055986L true NO20055986L (no) 2006-02-13

Family

ID=34055974

Family Applications (1)

Application Number Title Priority Date Filing Date
NO20055986A NO20055986L (no) 2003-07-09 2005-12-16 Forbindelse for behandling og forebygging av virale infeksjonssykdommer

Country Status (18)

Country Link
US (1) US7378446B2 (no)
EP (1) EP1661882B1 (no)
JP (1) JP4068639B2 (no)
KR (1) KR20060029182A (no)
CN (1) CN1819990B (no)
AU (1) AU2004255633B2 (no)
BR (1) BRPI0412459A (no)
CA (1) CA2531790A1 (no)
HK (1) HK1093485A1 (no)
IL (1) IL172666A0 (no)
MX (1) MXPA06000294A (no)
MY (1) MY143775A (no)
NO (1) NO20055986L (no)
NZ (1) NZ545102A (no)
RU (1) RU2346933C2 (no)
TW (1) TWI330173B (no)
UA (1) UA92134C2 (no)
WO (1) WO2005005372A1 (no)

Families Citing this family (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2006077004A (ja) * 2004-08-11 2006-03-23 Chugai Pharmaceut Co Ltd 抗ｈｃｖ作用を有する化合物およびそれを含む医薬組成物
WO2006016657A1 (ja) 2004-08-11 2006-02-16 Chugai Seiyaku Kabushiki Kaisha Hcv感染症を治療または予防するための薬剤
JPWO2006088071A1 (ja) * 2005-02-17 2008-07-03 中外製薬株式会社 抗ｈｃｖ作用を有する化合物の製造方法およびその中間体
JPWO2007000994A1 (ja) * 2005-06-28 2009-01-22 中外製薬株式会社 抗ｈｃｖ作用を有する化合物の製造方法
CN101360736A (zh) * 2005-11-23 2009-02-04 阿斯利康(瑞典)有限公司 L-丙氨酸衍生物
CN101489580A (zh) 2006-05-16 2009-07-22 财团法人东京都医学研究机构 治疗或预防hcv感染症的药物组合物
EP2049490A1 (en) * 2006-06-09 2009-04-22 Astra Zeneca AB N-(benzoyl)-o- [2- (pyridin- 2 -ylamino) ethyl]-l-tyrosine derivatives and related compounds as a5b1 antagonists for the treatment of solid tumors
US20090062267A1 (en) * 2007-01-29 2009-03-05 Astrazeneca Ab L-ALANINE DERIVATIVES AS a5beta1 ANTAGONISTS
WO2008125811A1 (en) * 2007-04-11 2008-10-23 Astrazeneca Ab N-[HETEROARYLCARBONYL]-S-THIENYL-L-ALANINE DERIVATIVES AS α5β1 ANTAGONISTS
TW201010692A (en) * 2008-06-19 2010-03-16 Public Univ Corp Nagoya City Univ Pharmaceutical composition for treatment or prevention of hbv infection
WO2010061881A1 (ja) 2008-11-26 2010-06-03 中外製薬株式会社 Ｃ型肝炎ウイルスの働きを阻害するオリゴリボヌクレオチドまたはペプチド核酸
JP2013121935A (ja) 2011-12-12 2013-06-20 Institute Of Microbial Chemistry 化合物、及び不斉合成反応
US9266853B2 (en) 2012-08-17 2016-02-23 Chugai Seiyaku Kabushiki Kaisha Orally available viridiofungin derivative possessing anti-HCV activity

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0526936A3 (en) 1991-08-02 1993-05-05 Merck & Co. Inc. Cholesterol-lowering agents
US5364948A (en) 1991-08-02 1994-11-15 Merck & Co., Inc. Biologically active compounds isolated from aerobic fermentation of Trichoderma viride
US5503973A (en) 1992-05-29 1996-04-02 The Regents Of The University Of California Method for inhibition of viral morphogenesis
EP1002793B1 (en) * 1997-06-09 2003-09-24 Takara Bio Inc. Physiologically active substances tkr2449, process for producing the same, and microorganism
JP5025051B2 (ja) 2001-07-26 2012-09-12 サトーホールディングス株式会社 印字編集処理装置
JP4093534B2 (ja) 2002-03-15 2008-06-04 スタンレー電気株式会社 車両用前照灯
MY141506A (en) 2003-02-12 2010-05-14 Chugai Pharmaceutical Co Ltd Virus therapeutic drug

Also Published As

Publication number Publication date
AU2004255633A1 (en) 2005-01-20
US7378446B2 (en) 2008-05-27
CN1819990A (zh) 2006-08-16
RU2346933C2 (ru) 2009-02-20
HK1093485A1 (en) 2007-03-02
KR20060029182A (ko) 2006-04-04
MY143775A (en) 2011-07-15
MXPA06000294A (es) 2006-04-18
US20060194870A1 (en) 2006-08-31
UA92134C2 (ru) 2010-10-11
RU2006103803A (ru) 2006-08-10
NZ545102A (en) 2008-11-28
AU2004255633B2 (en) 2009-08-06
CN1819990B (zh) 2010-04-21
JPWO2005005372A1 (ja) 2006-08-24
EP1661882A4 (en) 2007-01-31
EP1661882B1 (en) 2013-10-30
JP4068639B2 (ja) 2008-03-26
WO2005005372A1 (ja) 2005-01-20
EP1661882A1 (en) 2006-05-31
IL172666A0 (en) 2006-04-10
TW200524847A (en) 2005-08-01
BRPI0412459A (pt) 2006-10-17
TWI330173B (en) 2010-09-11
CA2531790A1 (en) 2005-01-20

Similar Documents

Publication Publication Date Title
NO20055986L (no) Forbindelse for behandling og forebygging av virale infeksjonssykdommer
NO20070751L (no) Inhibitorer av HCV-replifikasjon
NO20062339L (no) Hepatitt C virus-inhibitoerer
NO20044807L (no) Heratitt C virus inhibitorer
WO2006027628A3 (en) Naphthalimide derivatives as antiviral agents
NO20065075L (no) Ikke-nukleosidbaserte revers-transkriptase-inhibitorer.
WO2005084192A3 (en) Novel 2’-c-methyl nucleoside derivatives
WO2003015798A1 (en) Novel virus proliferation inhibition/virucidal method and novel pyradine nucleotide/pyradine nucleoside analogue
NO20070247L (no) Amino-5,5-difenylimidazolonderivater for inhibisjon av beta-sekretase
WO2006039488A3 (en) Hcv ns3-ns4a protease inhibition
NO20062267L (no) Hepatitt C virus inhibitorer
NO20081846L (no) Bifenylderivater og deres anvendelse ved behandling av hepatitt C
WO2005094329A8 (en) Compouns, compositions, processes of making, and methods of use related to inhibiting macrophage migration inhibitory factor
NO20063479L (no) Fosfonater, monofosfonamidater og bis-fosfonamidater for behandling av virussykdommer
WO2007038507A3 (en) Modified 4'-nucleosides as antiviral agents
MY146669A (en) Pyrazole derivatives for treating hiv
NO20062185L (no) Hepatitt C virus-inhibitorer
GEP20094826B (en) 3- or 4-monosubstituted phenol and thiophenol derivatives useful as h3 ligands
CY1113038T1 (el) Τριετεροκυκλικες ενωσεις, συνθεσεις, και μεθοδοι για τη θεραπεια καρκινου
GEP20094751B (en) Inhibitors of hepatitis c virus rna-dependent rna polymerase, and compositions and treatments using the same
EA200701504A1 (ru) Индолы, пригодные для лечения воспалений
EA200900156A1 (ru) Пиридазиновое соединение (варианты), способ его получения (варианты), способ лечения или профилактики инфекционного вирусного гепатита с с его помощью, композиция и лекарственное средство на его основе
WO2004060308A3 (en) Thiosemicarbazones as anti-virals and immunopotentiators
NO20091707L (no) Inhibitorer av hepatitt C virus
EA201270275A1 (ru) Кристаллическое соединение пиридазина

Legal Events

Date Code Title Description
FC2A Withdrawal, rejection or dismissal of laid open patent application